What we read

For this preview profile we synthesized: approximately 90 r/Peptides comments mentioning Pure Rawz between December 2025 and April 2026; the vendor's published COAs on the GLP-1 SKUs (retatrutide, tirzepatide, semaglutide) and the healing-peptide flagships (BPC-157, TB-500); and Janoshik public-test entries where batch IDs were traceable. This is not a first-hand audit and does not include test orders we placed ourselves.

Why Pure Rawz sits where it does

Pure Rawz has been operating in the US-domestic research-peptide market for several years — long enough to predate the 2025 shutdown wave. It was not one of the most-recommended vendors at the top of the market (Peptide Sciences and Amino Asylum held that position through 2024), but it was consistently named as a stable secondary option: the vendor people moved to when they wanted variety, lower prices on specific SKUs, or a backup source.

The vendor profile that emerges from public data:

• US-domestic operation: ships within the US. Domestic shipping reports cluster around 3–5 days, slightly slower than the cycle's fastest US-domestic vendors but consistent.
• COA practices: vendor publishes third-party COAs on the GLP-1 flagships and on BPC-157 / TB-500. COA discipline on the long tail (less-popular research peptides) is reported by community sources as less consistent — some SKUs have published COAs, others do not.
• Catalog breadth: covers the GLP-1 mainstream plus an unusually wide tail of ancillary research compounds. This is part of the vendor's positioning — breadth, not flagship purity.
• Pricing: positioned on the lower side of the cycle median for the GLP-1 SKUs we tracked. Roughly 5–15% below mid-tier vendors on retatrutide and tirzepatide.

Community sentiment

The dominant theme in r/Peptides comments was stability, not excellence. Pure Rawz was rarely described as the best option for any single dimension — fastest shipping, cleanest COAs, lowest prices — but it was repeatedly named as the vendor that "consistently shipped what was ordered" with "no surprises" across multi-year ordering histories.

Secondary themes included:

• Pricing as the primary draw — multiple commenters cited Pure Rawz as the price-competitive option for stacked orders
• Customer service as the primary friction — reports of slow responses (24–72 hours) on edge-case inquiries; this lowered the community-derived support subscore relative to peers
• COA depth on niche SKUs — the long-tail catalog is where community confidence drops; flagship SKUs get higher confidence

The most-cited concern was inconsistency on the long tail. Buyers ordering the GLP-1 mainstream (retatrutide, tirzepatide, semaglutide) reported a different experience than buyers ordering less-common research peptides, where COA quality and packaging discipline were described as more variable.

What we'd verify in a full audit

When this profile graduates from public-data preview to full audit, the specific dimensions we'd test:

• Independent Janoshik HPLC + mass-spec on retatrutide and at least one long-tail SKU; cross-reference vendor-stated COA against our independent result within our 1.5-percentage-point tolerance — the long-tail check is the differentiator for this vendor specifically
• Three test orders placed under aliases through a US receiving address; median dispatch and transit time logged
• Customer-service response time tested with one realistic and one deliberately confusing inquiry, business hours; the community signal on slow responses is the specific claim our audit needs to verify
• Endotoxin and sterility verification on at least one batch

Sources

• r/Peptides community threads (Dec 2025 – Apr 2026, ~90 comments synthesized)
• Vendor-published COAs at purerawz.co
• Janoshik public tests database — verify any cited COA QR codes against the source-of-truth
• The Peptide Catalog — vendor stability rankings — for cross-reference on community positioning